Pediatric Solid Tumor Metabolism [A Prospective Study Exploring Metabolism of Solid Tumors in Pediatrics]

Completed

Brief Summary: To explore metabolic phenotypes of children with extra-cranial solid tumors and compare these with their histopathological and genetic alterations to discover potential novel biomarkers and therapeutic targets to improve outcomes in children with high risk disease.

Detailed Description: The principal objective of this study is the metabolic characterization of pediatric solid tumors, with a particular focus on neuroblastoma (NBL) and fusion positive sarcoma (FPS), which will allow the detection of tumor specific metabolic alterations that can be exploited with the aim of developing novel therapeutic strategies and biomarkers.

Cellular metabolism studies provide insight, in a complementary way to genomics, into processes acting downstream from oncogenes and oncogenic fusion proteins, and such insight may point toward previously unrecognized therapeutic targets or onco-metabolites that are traceable as robust biomarkers for response. The investigator's new approach to use an in-vivo comprehensive analysis of metabolic reprograming in FPS/NBL has never been performed in childhood FPS/NBL and will complement genomics studies for these cancers. For this study, the investigators plan to obtain tumor samples at time of surgical biopsy/resection and study their metabolic signatures.

Recruitment & Eligibility

Inclusion Criteria

Suspected malignancy
Age ≤ 26 years and being cared for at Children's Medical Center
Ability to undergo standard of care diagnostic procedure, including biopsy or resection of the tumor, in the OR or IR at CMC

Exclusion Criteria

Arm && Interventions

Group	Intervention	Description
13C-glucose infusion	13C-glucose	Tumor samples of patients who receive the optional 13C-glucose infusion will be studied using flux analysis and metabolomic profiling.
No 13C-glucose infusion	No glucose infusion	Tumor samples of patients who do not choose to receive the optional 13C-glucose infusion will be studied using metabolomic profiling alone.

Primary Outcome Measures

Name	Time	Method
Metabolic phenotypes	2 years	Upon collection of tumor samples, they will be processed and analyzed with mass spectrometry to learn how the tumor processes the labeled glucose by assessing enrichment of metabolites to identify the active metabolic pathways in each tumor (metabolic phenotype)
Compare the metabolic phenotype with the result of histopathological diagnosis and genetic alterations of the specific tumor	2 years	We will collect data and information from the patient's medical record including pathologic diagnosis and genetic testing results throughout their treatment

Secondary Outcome Measures

Name	Time	Method
Metabolic evolution of tumors over time	2 years	Compare tumor metabolism at different points in therapy (diagnosis, metastasis, recurrence) if the family consents to further studies as their child's condition progresses. Will compare high risk samples to low risk samples within a diagnosis (IE: high risk neuroblastoma vs low risk neuroblastoma)
Metabolic change due to chemotherapy	2 years	Compare tumor metabolism at different points in therapy (before vs after chemotherapy is given) if the family consents to further studies as their child's condition progresses. For example, tumor sample at time of neuroblastoma biopsy to resection a few months later prior to bone marrow transplantation.
Metabolic phenotypes and outcomes	2 years	Assess for correlations between metabolism and patient outcome if applicable

Receive instant email notifications about changes in this clinical trial

Receive instant email notifications about changes in this clinical trial